Atrial tachycardia (AT) is a supraventricular tachycardia originating from a discrete atrial site outside the sinus node, characterized by a regular atrial rhythm >100 bpm with discrete P waves. [1-2] It accounts for approximately 10–17% of SVTs referred for ablation and can be focal (single origin) or multifocal (≥3 P-wave morphologies). [3-4] The following is a comprehensive clinical summary organized for emergency medicine and primary care workflows.
1. History
- Onset/offset: Focal AT due to automaticity often has a "warm-up" phenomenon (rate gradually increases over 5–10 seconds); microreentrant AT starts and stops abruptly. This contrasts with sinus tachycardia, which accelerates and decelerates gradually. [3][5]
- Symptom characterization: Palpitations, lightheadedness, chest discomfort, dyspnea, anxiety, fatigue. Severity is variable — some patients are asymptomatic. [2][6]
- Duration and frequency: Paroxysmal vs. incessant. Incessant AT can cause tachycardia-mediated cardiomyopathy in up to 10% of patients. [2][7]
- Triggers: Caffeine, alcohol, stimulants (cocaine, amphetamines), β-agonists, theophylline, stress, exercise. [3][8]
- Important negatives: Syncope (suggests hemodynamic compromise or alternative diagnosis), chest pain at rest (ACS), prior cardiac surgery (macroreentrant AT).
2. Alarm Features
- Hemodynamic instability: hypotension, altered mental status, signs of shock, acute heart failure [9]
- Syncope or presyncope
- Wide QRS complex tachycardia (concern for VT or pre-excited SVT)
- Signs of pre-excitation (delta wave) — risk of sudden cardiac death with WPW [4]
- New-onset heart failure symptoms (suggests tachycardia-mediated cardiomyopathy) [10]
- AT with AV block — classic for digoxin toxicity [8]
3. Medications
Drugs that cause AT: [8]
- β-agonists (albuterol, terbutaline), theophylline (especially levels >20 μg/mL)
- Digoxin (toxicity → paroxysmal AT with AV block)
- Stimulants: caffeine, cocaine, amphetamines, cannabis
- Phosphodiesterase inhibitors (milrinone, aminophylline)
Acute treatment medications: [2][9]
- Adenosine 6 mg rapid IV push → 12 mg if needed (diagnostic and therapeutic; terminates triggered AT, transiently suppresses automatic AT, reveals atrial activity with AV block) [2]
- IV diltiazem (20 mg) or verapamil (5 mg) for rate control or termination [4][9]
- IV beta-blockers (metoprolol) for hemodynamically stable patients [9]
- IV amiodarone if reduced EF or heart failure [2]
Long-term medications: [2][4]
- First-line: oral beta-blockers, diltiazem, or verapamil
- Second-line: flecainide or propafenone (contraindicated in structural/ischemic heart disease) [2]
- Third-line: sotalol, amiodarone, dofetilide (specialist initiation) [2]
- "Pill-in-the-pocket" approach with flecainide for infrequent episodes [4]
Contraindicated medications
- Adenosine in asthma (severe bronchospasm risk) and in AF with pre-excitation (WPW) [4]
- Verapamil/diltiazem in HFrEF or hemodynamic instability [9]
- Flecainide/propafenone in structural or ischemic heart disease [11]
- Non-selective beta-blockers in bronchospastic disease [12]
4. Diet
- Caffeine: Can trigger AT via phosphodiesterase inhibition; counsel moderation [8]
- Alcohol: Sympathetic stimulation and shortened atrial refractory period; limit intake [3][8]
- Hydration: Dehydration can exacerbate tachycardia; maintain adequate fluid intake
- Electrolytes: Ensure adequate magnesium and potassium intake (hypomagnesemia is a risk factor, especially for MAT) [2]
5. Review of Systems
- Cardiovascular: Palpitations, chest pain, dyspnea on exertion, orthopnea, edema (cardiomyopathy)
- Pulmonary: Cough, wheezing, dyspnea (pulmonary disease → MAT) [2]
- Endocrine: Heat intolerance, weight loss, tremor (hyperthyroidism) [3]
- Psychiatric: Anxiety, panic attacks (can mimic or trigger SVT) [13]
- Neurologic: Syncope, presyncope, dizziness
- Substance use: Caffeine, alcohol, tobacco, stimulant drugs, energy drinks [14]
6. Collateral History and Family History
- Prior episodes of SVT, prior ablation procedures, or cardiac surgery (risk for macroreentrant AT)
- Family history of pre-excitation syndromes (familial WPW), sudden cardiac death, or cardiomyopathy
- Medication list review — especially digoxin, theophylline, β-agonists [8]
- Occupational relevance: pilots, commercial drivers, heavy equipment operators require cardiology referral [3]
7. Risk Factors
- Focal AT: Often occurs in otherwise healthy young adults; prevalence increases with age [3-4]
- Multifocal AT: Pulmonary disease (COPD, acute exacerbation), pulmonary hypertension, coronary artery disease, valvular heart disease, hypomagnesemia, theophylline use [2]
- Structural heart disease, prior atrial surgery, congenital heart disease [3]
- Stimulant use (caffeine, cocaine, amphetamines) [8]
- Hyperthyroidism, electrolyte disturbances [3]
- Digoxin use (especially with renal impairment) [8]
- High premature atrial complex burden (>500/24h) increases risk of progression to AF [7]
8. Differential Diagnosis
- Sinus tachycardia — gradual warm-up/cool-down; identical P-wave morphology to baseline; look for underlying cause [3][5]
- AVNRT — most common SVT; short RP tachycardia; pseudo R' in V1 or pseudo S in inferior leads [15]
- AVRT (orthodromic) — short RP; look for pre-excitation (delta wave) in sinus rhythm [15]
- Atrial flutter — sawtooth pattern without isoelectric baseline between atrial waves; typically ~300 bpm atrial rate with 2:1 block [4]
- Atrial fibrillation — irregularly irregular; no discrete P waves [4]
- Multifocal AT — ≥3 P-wave morphologies, irregularly irregular rhythm; associated with pulmonary disease [2][4]
- Inappropriate sinus tachycardia — diagnosis of exclusion; normal P-wave morphology; mean 24h HR >90 bpm [5]
- Junctional tachycardia — narrow complex, may have AV dissociation
The following algorithm from the 2015 ACC/AHA/HRS SVT Guidelines illustrates the systematic approach to differentiating narrow QRS complex tachycardias:
9. Past Medical History
- Prior SVT episodes or ablation procedures
- Structural heart disease, cardiomyopathy, valvular disease
- COPD or other pulmonary disease (especially relevant for MAT) [2]
- Hyperthyroidism or other endocrine disorders
- Congenital heart disease or prior cardiac surgery
- Chronic kidney disease (affects digoxin clearance) [8]
10. Physical Exam
- Vitals: Tachycardia (rate typically 100–250 bpm), blood pressure (hypotension = unstable), oxygen saturation [2]
- Cardiovascular: Regular rapid rhythm (focal AT) vs. irregular (MAT); cannon A waves in JVP if AV dissociation; signs of heart failure (S3, JVD, peripheral edema)
- Pulmonary: Wheezing, crackles (underlying pulmonary disease or heart failure)
- Thyroid: Goiter, tremor, exophthalmos
- Neurologic: Mental status assessment (hemodynamic compromise)
- Focused maneuver: Carotid sinus massage — may transiently slow ventricular rate or reveal underlying atrial activity; avoid in patients with carotid bruit or known stenosis [4][9]
11. Lab Studies
- BMP/CMP: Electrolytes (K⁺, Mg²⁺, Ca²⁺), renal function [2]
- TSH: Rule out hyperthyroidism [3]
- CBC: Anemia as a contributor to tachycardia
- Digoxin level if on digoxin (toxicity at levels >2 ng/mL) [8]
- Theophylline level if applicable (toxicity at >20 μg/mL) [8]
- Troponin: If chest pain or concern for demand ischemia
- BNP/NT-proBNP: If concern for heart failure or tachycardia-mediated cardiomyopathy [10]
- Urine drug screen: If stimulant use suspected
12. Imaging
- Echocardiogram: Recommended to assess for structural heart disease, valvular abnormalities, and LV function (especially to evaluate for tachycardia-mediated cardiomyopathy) [5][10]
- Chest X-ray: If pulmonary disease suspected or signs of heart failure
- CT angiography: Only if pulmonary embolism is in the differential
- Imaging is not required emergently if the patient is hemodynamically stable and converts to sinus rhythm
13. Special Tests
- Ambulatory monitoring: Holter monitor (24–48h) or event recorder for paroxysmal episodes; helps distinguish AT from sinus tachycardia by demonstrating abrupt onset [3][6]
- Electrophysiology study (EPS): Gold standard for definitive diagnosis and mechanism determination; required before catheter ablation [11][17]
- Adenosine challenge: Diagnostic — AT persists with transient AV block (revealing atrial activity), whereas AVNRT/AVRT typically terminate [2][4]
- P-wave morphology algorithms: Leads V1 and II most useful; positive V1 with negative I/aVL suggests left atrial origin [2][11]
14. ECG
Key ECG features of focal AT: [3-4][15]
- Regular narrow QRS tachycardia (100–250 bpm)
- Discrete P waves with isoelectric baseline between them (distinguishes from flutter)
- P-wave morphology often differs from sinus P wave (except crista terminalis origin)
- Long RP interval (RP > PR) — P wave typically in the second half of the tachycardia cycle [15][17]
- 1:1 AV conduction is typical, but AV block during tachycardia excludes AVRT and makes AVNRT very unlikely [17]
- Warm-up phenomenon at onset (automatic mechanism) [3]
Multifocal AT ECG: [2][11]
- ≥3 distinct P-wave morphologies
- Irregularly irregular rhythm (can mimic AF)
- Variable P-P, P-R, and R-R intervals
- Isoelectric baseline between P waves (unlike AF)
Dangerous patterns
- AT with AV block → digoxin toxicity until proven otherwise [8]
- Pre-excitation (delta wave) in sinus rhythm → WPW, requires cardiology referral [4]
15. Assessment
- Focal AT in adults is usually benign but can cause tachycardia-mediated cardiomyopathy if incessant (up to 10% of patients referred for ablation). EF typically normalizes after successful treatment. [2][7][11]
- MAT carries a higher mortality related to the severity of underlying disease (pulmonary, cardiac) rather than the arrhythmia itself. [2]
- Severity stratification: hemodynamic stability, symptom burden, duration (paroxysmal vs. incessant), and presence of cardiomyopathy guide management intensity.
- Atypical presentations: AT originating near the sinus node can mimic sinus tachycardia; abrupt onset/offset on monitoring is the key distinguishing feature. [5][11]
16. Treatment Plan
Acute management (hemodynamically unstable)
- Synchronized cardioversion[4][9][17]
Acute management (hemodynamically stable): [2][9]
- Vagal maneuvers (modified Valsalva with passive leg raise improves success to ~50%) [9]
- Adenosine 6 mg rapid IV push → 12 mg if no response (both diagnostic and therapeutic) [2]
- IV diltiazem 20 mg or verapamil 5 mg over 2 min for rate control/termination [9]
- IV beta-blocker (metoprolol) as alternative [9]
- IV amiodarone if reduced EF [2]
Long-term management: [2-3][11]
- Catheter ablation is first-line for recurrent symptomatic focal AT (acute success >90–95%, recurrence <5%) [6][11]
- If ablation not desired/feasible: beta-blockers, diltiazem, or verapamil (first-line pharmacotherapy) [2]
- Flecainide or propafenone (second-line, no structural heart disease) [2]
- Sotalol or amiodarone (third-line, specialist supervision) [2]
Multifocal AT: [2][11]
- Treat the underlying condition first (COPD exacerbation, correct hypoxia, acid-base disturbances)
- IV magnesium (even if levels are normal) [2]
- Verapamil or diltiazem for rate control (preferred in pulmonary disease) [2]
- Metoprolol with caution after respiratory stabilization [2]
- Cardioversion is NOT effective for MAT [2]
- Antiarrhythmics generally not helpful [2]
17. Disposition
Admission criteria
- Hemodynamic instability or refractory tachycardia
- New-onset heart failure or suspected tachycardia-mediated cardiomyopathy [10]
- Suspected digoxin toxicity (AT with AV block) [8]
- MAT with acute pulmonary decompensation [2]
- Wide complex tachycardia or pre-excitation requiring monitoring
- Need for IV antiarrhythmic initiation
Discharge criteria
- Converted to sinus rhythm and hemodynamically stable
- No evidence of structural heart disease or cardiomyopathy
- Infrequent, brief, well-tolerated episodes [3]
- Reliable follow-up arranged
Specialist consultation triggers: [3]
- Recurrent symptomatic episodes despite medical therapy
- Pre-excitation or delta wave on ECG
- Syncope
- Known structural heart disease
- Uncertainty about diagnosis or management
- High-risk occupation (pilot, commercial driver)
- Consideration for catheter ablation
18. Follow Up / Return Precautions
- Follow-up timing: Cardiology referral within 1–2 weeks for recurrent AT; sooner if symptomatic or new cardiomyopathy suspected
- Return immediately for: Syncope, sustained palpitations >15–20 minutes unresponsive to vagal maneuvers, chest pain, severe dyspnea, lightheadedness
- Patient counseling:
- Teach vagal maneuvers (modified Valsalva) for self-termination [11]
- Avoid known triggers (caffeine, alcohol, stimulants) [3]
- Medication adherence if prescribed rate-control or antiarrhythmic therapy
- Expected course: Focal AT is generally benign; ~50% of patients with infrequent episodes may become asymptomatic over time. Incessant AT requires definitive treatment (ablation) to prevent cardiomyopathy. [3][10-11]
- Post-ablation: Success rate >90–95%; recurrence rate <5%; risk of inadvertent heart block <1% [6][11]
References
1. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Writing Committee Members, Joglar JA, Chung MK, et al. Journal of the American College of Cardiology. 2024.
2. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Journal of the American College of Cardiology. 2016.
3. Common Types of Supraventricular Tachycardia: Diagnosis and Management. — Nasir M, Sturts A, Sturts A. American Family Physician. 2023.
4. Diagnosis and Management of Paroxysmal Supraventricular Tachycardia. — Peng G, Zei PC. The Journal of the American Medical Association. 2024.
5. Inappropriate Sinus Tachycardia: Etiology, Pathophysiology, And Management: JACC Review Topic of the Week. — Ahmed A, Pothineni NVK, Charate R, et al. Journal of the American College of Cardiology. 2022.
6. Diagnosis and Management of Common Types of Supraventricular Tachycardia. — Helton MR. American Family Physician. 2015.
7. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus on Risk Assessment in Cardiac Arrhythmias: Use the Right Tool for the Right Outcome, in the Right Population. — Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, et al. Heart Rhythm. 2020.
8. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. — Tisdale JE, Chung MK, Campbell KB, et al. Circulation. 2020.
9. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Wigginton JG, Agarwal S, Bartos JA, et al. Circulation. 2025.
10. Tachycardia and Atrial Fibrillation-Related Cardiomyopathies: Potential Mechanisms and Current Therapies. — Keefe JA, Garber R, McCauley MD, Wehrens XHT. JACC. Heart Failure. 2024.
11. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Heart Rhythm. 2016.
12. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. — January CT, Wann LS, Alpert JS, et al. Circulation. 2014.
13. Inappropriate Sinus Tachycardia. — Olshansky B, Sullivan RM. Journal of the American College of Cardiology. 2013.
14. Palpitations: Evaluation, Management, and Wearable Smart Devices. — Gauer RL, Thomas MF, McNutt RA. American Family Physician. 2024.
15. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Heart Rhythm. 2016.
16. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Page RL, Joglar JA, Caldwell MA, et al. Journal of the American College of Cardiology. 2016.
17. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in Collaboration With NASPE-Heart Rhythm Society. — Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. Journal of the American College of Cardiology. 2003.